Infectious diseases now · 2025
Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chiabi Andreas, Nykam Sankara, Kan Kate, Fomenky Cecilia, Tanlaka Lucas M, Ngueiwoh Franklin N, Ewane Christabelle, Fozao Vanessa M, Nsame Denis
Аннотация
OBJECTIVES: Cameroon adopted dolutegravir-based regimen in 2020 as the first-line treatment of HIV infection, as recommended by the World Health Organization on the basis of efficacy, high genetic barriers to drug resistance, low toxicity, and low cost. Our main objective was to evaluate the efficacy of dolutegravir-based regimen among HIV-infected children.
PATIENTS AND METHODS: We performed a retrospective hospital-based cohort study over a 5-month period at the pediatric day care unit of Bamenda Regional Hospital among HIV-infected children aged 3-15 years. Data was collected using a predesigned questionnaire and was analyzed with SPSS v.27.0 using the appropriate statistical test. P-values < 0.05 were considered statistically significant.
RESULTS: We included 207 participants: 139 in the efavirenz (EFV) group and 68 in the dolutegravir (DTG) group. The mean viral load was lower in the DTG group than in the EFV group with mean viral load differences of 3,679copies/ml, 2,245copies/ml, and 3,207copies/ml at 6 months, 12 months, and 24 months, respectively. The viral load suppression rate was higher in the DTG group than in the EFV group at 6 months (63.2 % vs 51.1 %, p = 0.099), at 12 months (80.9 % vs 64.7 %, p = 0.017), and at 24 months (83.8 % vs 70.5 %, p = 0.038). Children on DTG achieved virologic suppression quicker than children on EFV (9 months vs 10 months, p = 0.178).
CONCLUSION: Children on dolutegravir had good viral load suppression compared with children on efavirenz.
PATIENTS AND METHODS: We performed a retrospective hospital-based cohort study over a 5-month period at the pediatric day care unit of Bamenda Regional Hospital among HIV-infected children aged 3-15 years. Data was collected using a predesigned questionnaire and was analyzed with SPSS v.27.0 using the appropriate statistical test. P-values < 0.05 were considered statistically significant.
RESULTS: We included 207 participants: 139 in the efavirenz (EFV) group and 68 in the dolutegravir (DTG) group. The mean viral load was lower in the DTG group than in the EFV group with mean viral load differences of 3,679copies/ml, 2,245copies/ml, and 3,207copies/ml at 6 months, 12 months, and 24 months, respectively. The viral load suppression rate was higher in the DTG group than in the EFV group at 6 months (63.2 % vs 51.1 %, p = 0.099), at 12 months (80.9 % vs 64.7 %, p = 0.017), and at 24 months (83.8 % vs 70.5 %, p = 0.038). Children on DTG achieved virologic suppression quicker than children on EFV (9 months vs 10 months, p = 0.178).
CONCLUSION: Children on dolutegravir had good viral load suppression compared with children on efavirenz.